BIOTECH XYZ’s Post

Join me on Feb 7th for a panel discussion on the tech trends driving the healthcare revolution. I'm moderating a chat with Jane Buus Laursen, Erki Mölder, Catarina Flyborg and Matti Ahlqvist, MBA on the best ways for tech start ups to succeed in Life Science, how to partner, commercialise and scale, And of course - how to spot the next big thing 🔍 Catch us on the main stage at GoWest - Nordic Venture Capital Forum 👈 See you there! #gowest2024 #gowest24 #healthcare #techentrepreneurship #healthtech #lifescience #techpanel #innovation #venturecapital

Like science founders know all too well that running a lean organization and keeping costs down are vital for hitting milestones and attracting additional capital (especially in today's challenging funding climate). Join us for a three-part series to SPEED UP & DE-RISK your venture: April 4, April 18, May 2 Extend cash runway and maximize potential with a virtual biotech model. Register now and join the conversation! https://lnkd.in/g__qagsV #StartupLife #VirtualBiotech #RegisterToday

𝗪𝗵𝗼 𝗮𝗿𝗲 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗮𝗰𝘁𝗶𝘃𝗲 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝗳𝗼𝗿 𝘀𝗲𝗲𝗱 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗲𝘀 𝗔 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵 𝘁𝗲𝗰𝗵 𝗶𝗻 𝗕𝗲𝗹𝗴𝗶𝘂𝗺?💡 Dive into the full list of the most active VC investors in Belgian health tech and uncover valuable perspectives on their areas of interest and the range of projects they support 👇🏼 #HealthTechInnovations #HealthTech #FutureOfHealthcare #VentureCapital #Investors

Navigating the Biotech Surge 🚀 Boston's biotech landscape in 2024 is a testament to innovation! From startup incubators to industry giants, we're seeing a remarkable convergence of talent and technology. 💡🧬 Despite global economic tremors, biotech has stood resilient, cueing in a record-breaking number of IPOs this year. The key? Collaboration. The tight-knit community here fosters partnerships that are pushing medical boundaries, with a remarkable spotlight on personalized medicine. It's incredible to witness how these synergies are speeding up drug development pipelines - something that once took decades is now unfolding in years, if not months. And let's talk investment 💲💹 - Boston biotech is a hotbed for venture capital, with funding rounds catapulting startups onto the global stage. But it's not just about the money; it's about the purpose-driven zeal of entrepreneurs set on solving complex health challenges. As someone embedded in this ecosystem, I can't help but marvel at our pace. Are we on the cusp of the next big breakthrough? How do you see Boston's biotech innovation shaping our future? Share your thoughts! 🤝🌐 #BiotechBoom #BostonInnovation #HealthcareFutures

Thank you Trill Impact Advisory’s Ventures team, for hosting an event on the topic of defining and measuring #impact in #lifescience. 🙌 #venture experts within life science was gathered for insights and discussions on the business opportunities in serving underserved patient populations💡 Since Investinor is investing into life science, the topic on impact-investing is important for us for several reasons; 💸 since more capital is coming from impact-investors, it is important for us to get a better understanding of how these investors assess new investments and 💉 investing into life science can potentially give both high financial return and high social return; saving lives, better quality of life or extending time of life. Who doesn't want that? Thank you for sharing and for good discussions with Johann Bleivik Wist and my self; Adjuvant Capital, Aliath Bioventures, AMR Action Fund, Andera Partners, BioInnovation Institute, EQT Life Sciences, Forbion, Gilde Healthcare, Hadean Ventures, Industrifonden, NLC Health Ventures, Sofinnova Partners, SV Health Investors, Trill Impact and Thuja Capital.

Interesting blog post from Bruce Booth about the rate of company formation in biotech and the return of more disciplined investing by the venture community, which should, hopefully, lead to greater long-term returns. We in government relations are witnessing the same trend albeit from a different perspective - either way, the "pandemic bubble's overindulgence" was real! I'll also take this opportunity to say it behooves many companies to consider non-dilutive funding - such as from the federal government - as a complement to what they are seeking from private sources. It can also be a draw for additional private capital.

Since January 2019, #HealthTechAlpha has catalogued over 4,700 #deals involving #DigitalHealth ventures with a Clinical Evidence Signal of 40 or above. These #ventures, backed by clinical #proofpoints, are attracting major #investments, with Khosla Ventures leading the charge. With over 95 investments in ventures that have achieved significant #clinicalstrength, Khosla Ventures has solidified its position as the #top VC #investor in this space. 🌟 Why it matters: #Clinicalevidence has become a critical proof point for scaling Digital Health ventures and securing investor #confidence. This valuable insight is brought to you by Galen Growth | Insights You Can Trust research, powered by #HealthTechAlpha —the #1 resource for data, intel, and insights in digital technology innovation in healthcare.

#fundingalert 💼Company: Vivalyx  💰Funding: €5.4Million ⚡Round: Seed 👥Investors: Consortium, Brightlands Venture Partners, TVF | TechVision Fonds, Arve Capital, Thomas Ebeling, Andrej Henkler, Springboard Health Angels. Vivalyx GmbH, a biotech company was founded in 2022 in Aachen by Andreas Schumacher, Benedict Doorschodt, René H. Tolba, Christian Bleilevens, Malte Brettel, and Marius Rosenberg. The funding enables it to finance the clinical study required for regulatory approval. This crucial step paves the way for the launch of the innovative organ preservation solution, which has the potential to extend the lifespan of donor organs and enhance their vitality. Luc Starmans, Bernhard Kugel, Andrej Henkler Read more - https://lnkd.in/ggpZz5wE To share your startup story write us on - contact@startuprise.co.uk #Vivalyx #biotech #finance #vitality #funding #fundingnews #startupnews #startuprise

Whether you are a new or experienced investor the Longevity Investor Network by Lifespan.io provides 100+ deep tech longevity/ rejuvenation deal flow annually in therapeutics, diagnostics, medical devices, digital health, nutraceuticals, etc and free investor education seminars! The longevity field is still very new, but since the COVID epidemic received a lot of attention and billions of dollars of investment annually because people finally realized their survival depends on their biological age, not their chronological age. Many companies in this industry are successfully working on solutions not only to delay or slow down aging, but even to stop or reverse it, effectively rewinding the biological clock. Don't miss the investment opportunity of a (long) lifetime!

🚀 Dive into the world of Life Sciences and BioTech! 🌱 Discover a comprehensive list of 250 VC firms specializing in this innovative sector. Get insights on firm names, websites, offices, investment stages, and more! Check it out here: https://lnkd.in/dpcUtv6E #startup #startups #venturecapital #funding #vc #privateequity